EUVIMEDEUVIMED entdecken
Crossref

Novel splice variants implicated in inherited retinal dystrophies in two Moroccan families

Kenza El Khair, Aymane Bouzidi, Majida Charif, Hicham Charoute, Adil El Hamouchi, Hanane Serraj Filali, Houda Benrahma, Guy Lenaers, Abdelhamid Barakat

Molecular Biology Reports · 2025

DOI: 10.1007/s11033-025-10875-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biology Reports, 2025. Verfasst von Kenza El Khair und 8 weiteren Autor:innen. Beteiligte Einrichtung: Genomics and Human Genetics Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, Casablanca, 20360, Morocco. Hauptthemen laut MEDLINE: Retinal Dystrophies. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Inherited retinal dystrophies (IRD) are a group of conditions resulting in visual impairments or blindness, due to the dysfunction of the retina. It affects 1/2000 individuals worldwide, and over 324 genes and 20 phenotypes are implicated in these pathologies. The most common form of IRD is Retinitis Pigmentosa, followed by Stargardt diseases, Leber congenital amaurosis and cone/cone-rod dystrophies. Each form of IRDs presents different clinical features. This study aims to broaden the clinical and genetic investigations of IRD patients in Morocco. METHODS AND RESULTS: Whole exome sequencing was performed on the probands of two unrelated Moroccan families with IRD phenotypes, followed by Sanger sequencing to evaluate the segregation of candidate variants within family members. WES revealed two homozygous pathogenic splice-variants in CABP4:c.800-2 A > G and TTLL5:c.182-1G > T in the two families, and was confirmed by Sanger sequencing that revealed a second homozygous variant in TTLL5 c.182-5T > C in the second family. All parents were heterozygous. CONCLUSION: This study reports novel pathogenic variants in TTLL5 and CABP4 in patients with IRDs. These findings expand our knowledge of IRD causal genes in Moroccan patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal DystrophiesHumansMoroccoMalePedigreeFemaleExome SequencingAdultHomozygotePhenotypeMutation

Stichwörter der Autor:innen

CABP4TTLL5Inherited retinal dystrophySplice-site variantsWhole exome sequencing

Autor:innen und Institutionen

  • Genomics and Human Genetics Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, Casablanca, 20360, Morocco.
  • Interdisciplinary Laboratory of Biotechnology and Health, Mohammed VI Higher Institute of Biosciences and Biotechnology, Mohammed VI University of Sciences and Health (UM6SS), Casablanca, Morocco.
  • University of Angers, MitoLab, Unité MITOVASC, UMR CNRS 6015, INSERM U1083, SFR ICAT, University Hospital of Angers, Angers, France.
  • Genetics and Immuno-cell Therapy Team, Faculty of Sciences, Mohammed First University, Oujda, Morocco.
  • Research unit of epidemiology, biostatistics and bioinformatics, Institut Pasteur du Maroc, Casablanca, Morocco.
  • Genomic Sequencing Laboratory, Institut Pasteur du Maroc, Casablanca, Morocco.

Zitieren

APA

El Khair, K., Bouzidi, A., Charif, M., Charoute, H., El Hamouchi, A., Serraj Filali, H., Benrahma, H., Lenaers, G., & Barakat, A. (2025). Novel splice variants implicated in inherited retinal dystrophies in two Moroccan families. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-10875-8

Vancouver

El Khair K, Bouzidi A, Charif M, Charoute H, El Hamouchi A, Serraj Filali H, et al. Novel splice variants implicated in inherited retinal dystrophies in two Moroccan families. Molecular Biology Reports. 2025. doi:10.1007/s11033-025-10875-8

BibTeX
@article{ElKhair2025,
  author = {El Khair, Kenza and Bouzidi, Aymane and Charif, Majida and Charoute, Hicham and El Hamouchi, Adil and Serraj Filali, Hanane and Benrahma, Houda and Lenaers, Guy and Barakat, Abdelhamid},
  title = {Novel splice variants implicated in inherited retinal dystrophies in two Moroccan families},
  journal = {Molecular Biology Reports},
  year = {2025},
  doi = {10.1007/s11033-025-10875-8}
}
Kostenlos starten →